Pioglitazone - A review of its use in type 2 diabetes mellitus

被引：138

作者：

Waugh, J ^{[1
]}

Keating, GM ^{[1
]}

Plosker, GL ^{[1
]}

Easthope, S ^{[1
]}

Robinson, DM ^{[1
]}

机构：

[1] Adis Int Ltd, Auckland 1311, New Zealand

来源：

DRUGS | 2006年 / 66卷 / 01期

关键词：

pioglitazone; type 2 diabetes mellitus; thiazolidinedione; pharmacodynamics; pharmacokinetics; therapeutic use; pharmacoeconomics; tolerability;

D O I：

10.2165/00003495-200666010-00005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pioglitazone is an antihyperglycaemic agent that, in the presence of insulin resistance, increases hepatic and peripheral insulin sensitivity, thereby inhibiting hepatic gluconeogenesis and increasing peripheral and splanchnic glucose uptake. Pioglitazone is generally well tolerated, weight gain and oedema are the most common emergent adverse events, and there are no known drug interactions between pioglitazone and other drugs. In clinical trials in patients with type 2 diabetes mellitus, pioglitazone as monotherapy, or in combination with metformin, repaglinide, insulin or a sulphonylurea, induced both long- and short-term improvements in glycaemic control and serum lipid profiles. Pioglitazone was also effective in reducing some measures of cardiovascular risk and arteriosclerosis. Pioglitazone thus offers an effective treatment option for the management of patients with type 2 diabetes.

引用

页码：85 / 109

页数：25

共 104 条

[1]

American Diabetes Association, 2004, DIABETES CARE, V27, pS1

[2]

[Anonymous], 1995, Diabetes, V44, P1249

[3] Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study [J].